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Increased levels of a cleaved form of prolactin (molecular weight
16 kDa) have been associated with preeclampsia. To study the
effects of prolactin on blood pressure (BP), we generated male mice
with a single-copy transgene (Tg; inserted into the hypoxanthine-
guanine phosphoribosyltransferase locus) that enables inducible
hepatic production of prolactin and its cleavage product. The Tg is
driven by the indole-3-carbinol (I3C)-inducible rat cytochrome P450
1A1 promoter. When the Tg mice were fed normal chow (NC),
plasma prolactin concentrations were comparable to those in female
WT mice in the last third of pregnancy, and BP was lower than in WT
mice (∼95 mm Hg vs. ∼105 mm Hg). When the Tg mice were fed
chow containing IC3, plasma prolactin concentrations increased three-
fold, BP increased to ∼130 mm Hg, and cardiac function became
markedly impaired. IC3 chow did not affect the WT mice. Urinary ex-
cretion of nitrite/nitrate and the amount of Ser1177-phosphorylated
endothelial nitric oxide (NO) synthase (eNOS) were significantly
greater in the Tg mice fed NC than in WT mice, as they are during
pregnancy. However, when I3C was fed, these indicators of NO pro-
duction became significantly less in the Tg mice than in WT mice. The
effects of increased plasma prolactin were abolished by a genetic
absence of eNOS. Thus, a threefold increase in plasma prolactin is
sufficient to increase BP significantly and to markedly impair cardiac
function, with effects mediated by NO produced by eNOS. We sug-
gest that pregnant womenwith abnormally high prolactin levels may
need special attention.
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Prolactin, a 23-kDa polypeptide hormone, is a potent multi-functional cytokine with a broad range of biological effects,
including water and salt balance, lactogenesis, cell proliferation
and differentiation, testicular Leydig cell function, T-cell im-
munity, pancreatic β-cell function, hematopoiesis, and adipo-
genesis (1). Prolactin is physiologically secreted mainly from the
anterior lobe of pituitary gland. The secretion is negatively regu-
lated by dopamine and positively regulated by prolactin-releasing
peptide (2) synthesized in the hypothalamus. The levels of pro-
lactin in the serum, urine, and amniotic fluids are significantly
higher in patients with preeclampsia than in subjects with normal
pregnancy (3–5), suggesting that prolactin is involved in the
pathogenesis of pregnancy-associated hypertension. However,
animal experiments have shown inconsistent effects of prolactin
on blood pressure (BP). Thus, acute i.v. infusion of prolactin in-
creased BP in rabbits (6), but, when ovine prolactin was chronically
given i.p. via an osmotic minipump in rats, BP was decreased (7). It
has also been reported that chronic prolactin infusion caused an
increase in urinary sodium, potassium, and water excretion, but no
significant changes in arterial pressure, in rats (8).
To study the chronic effects of different plasma concentrations
of prolactin on BP and general well-being, we have generated
male mice with a single-copy transgene [Tg; inserted into the
hypoxanthine-guanine phosphoribosyltransferase (Hprt) locus]
that enables hepatic production of prolactin and its cleavage
product when the mice are fed indole-3-carbinol (I3C), a xeno-
biotic agent naturally present at high levels in broccoli and
similar vegetables. The Tg is leaky, and, when the mice are fed
normal chow (NC), it leads to basal prolactin levels comparable
to those in the plasma of WT female mice in the last third of a
normal pregnancy, accompanied by a decrease in BP and an in-
crease in nitric oxide (NO) production, likewise similar to those
occurring in females during pregnancy. When the Tg mice are fed a
diet containing IC3, plasma levels become threefold basal, BP in-
creases, and cardiac insufficiency develops. In the absence of en-
dothelial NO synthase (eNOS), these changes did not occur.
Results
Generation of Tg Mice Producing Prolactin in the Liver. Gene tar-
geting, as described previously (9), was used to insert a single-copy
Tg into the Hprt locus of the X chromosome. The Tg is comprised
of a copy of mouse cDNA for prolactin (Prl cDNA; Fig. 1A) driven
by the rat cytochrome P450 1A1 promoter (PCyp1a1) (10), with the
3′-UTR of the bovine growth hormone gene (bGH) in place of its
natural 3′-UTR. Male Tg mice fed NC have greater than WT ex-
pression of prolactin mRNA in the liver and a higher concentration
of prolactin in the plasma (16.1 ± 1.1 ng/mL vs. 5.1 ± 0.6 ng/mL),
indicating that the inducible Tg is leaky (Fig. 1 B and D). This basal
plasma prolactin concentration is close to that we observe in female
WT mice in the last third of pregnancy (15.3 ± 0.6 ng/mL). When
the Tg mice were fed I3C, hepatic prolactin mRNA levels were
markedly increased, and the plasma prolactin concentration be-
came approximately three times basal (Fig. 1 B and D). The ex-
pression of prolactin in the pituitary gland was not significantly
altered by the Tg or by the I3C diet (Fig. 1C).
Opposite Changes in BP in the Tg Mice with Modestly and Substantially
Increased Plasma Prolactin Levels.We found that the Tg mice fed NC
had a significantly lower BP than WT mice fed NC [WT (n = 9),
108 ± 1 mm Hg vs. Tg (n = 11), 97 ± 3 mm Hg; P < 0.05; Fig. 2A
and Fig. S1A], but the heart rate was not significantly different
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between Tg andWT [WT (n = 9), 635 ± 39 beats per minute (bpm)
vs. Tg (n = 11), 561 ± 17 bpm; Fig. 2B and Fig. S1A].
When the Tg mice were fed chow containing 3.0% I3C (wt/wt),
their BP was markedly higher than that in WT mice fed the I3C diet
[WT (n = 9), 106 ± 2 mm Hg vs. Tg (n = 11), 132 ± 3 mm Hg; P <
0.01; Fig. 2A], but their heart rates were not significantly different
[WT (n = 9), 555 ± 39 bpm vs. Tg (n = 11), 630 ± 25 bpm; Fig. 2B].
Urinary Excretion of Nitrite/Nitrate and Renal Expression of eNOS in
the Tg Mice. Renal excretion of nitrite/nitrate in the Tg mice fed
NC was significantly higher than in WT mice fed NC [WT (n = 8),
1.60 ± 0.27 μmol/d vs. Tg (n = 8), 3.44 ± 0.49 μmol/d; P < 0.05; Fig.
2C]. However, when I3C was fed, the Tg mice had significantly less
renal excretion of nitrite/nitrate than the WT mice [WT (n = 8),
1.55 ± 0.17 μmol/d vs. Tg (n = 8), 0.56 ± 0.15 μmol/d; P < 0.01;
Fig. 2C].
Urinary nitrite/nitrate has both dietary and endogenous origins
(10, 11). Because food consumption is not different in the WT and
Tg mice with or without I3C (Fig. 2D), we conclude that the dif-
ference in urinary excretion of nitrite/nitrate is a result of differences
in the endogenous production of NO. Water intake and creatinine
clearance were not different among the 4 groups (Fig. S1 B and C).
Renal mRNA and protein levels of eNOS were not changed by
the presence of the Tg or by the I3C diet (Fig. 2 E and F). How-
ever, the protein levels of Serine 1177-phosphorylated eNOS,
which is the active form of eNOS, were increased in the Tg mice
fed NC and decreased in the Tg mice fed the I3C diet (Fig. 2F).
Increased Expression of 16-kDa Prolactin in the Prolactin Tg Mice Fed
I3C. To determine total plasma prolactin (full-length plus 16 kDa),
we performed an immunoblot with an antibody raised against the
N-terminal peptide of prolactin. The result showed that total
prolactin is greater in the Tg mice fed NC than in WT mice fed
NC. The I3C diet increased total prolactin in the Tg mice but not
in the WT mice (Fig. 2G). A faint band corresponding to the
16-kDa form of prolactin is visible in the plasma sample from the
Tg mouse fed IC3, but whether this is because the cleaved form is
now a greater proportion of the total or is just a reflection of the
higher total amount is not clear.
This uncertainty was resolved by determining the renal ex-
pressions of genes for inducible NO synthase (iNOS) and plas-
minogen activator inhibitor-1 (PAI-1), both of which are induced
by the 16-kDa prolactin but not by full-length prolactin (12–14).
We found that the expressions of PAI-1 and iNOS were signif-
icantly increased only in the Tg mice fed IC3 (Fig. 2 H and I). We
conclude that only the Tg mice fed IC3 express the 16-kDa
fragment. Because it has been shown that the 16-kDa prolactin,
but not the full-length protein, decreases the activity of eNOS
(15, 16), this result suggests that 16-kDa prolactin plays a direct
role in the increase in BP that occurs in the Tg mice fed IC3 by
decreasing eNOS production of NO.
Deficiency of eNOS Abolishes the Effects of Prolactin on BP. To study
the role of eNOS in the regulation of BP by prolactin, we
crossbred the prolactin Tg mice with mice deficient in eNOS
(17). We found that the eNOS deficiency by itself did not sig-
nificantly change plasma levels of prolactin (Fig. 3A), but the
lack of eNOS abolished the differences in BP in the WT and Tg
mice with and without I3C (Fig. 3 B and C).
These findings show that eNOS plays a critical role in the
decrease in BP observed in the Tg mice fed NC and the increase
in BP seen in the Tg mice fed IC3.
Cardiac Dysfunction in the Mice with high Plasma Levels of Prolactin.
We used echocardiography.to determine the effects of the different
levels of plasma prolactin on cardiac function and structure. We
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Fig. 1. Generation of drug-inducible hypermorphic mice for prolactin. (A) The gene-targeting strategy (*P < 0.05 and **P < 0.01 vs. WT; NS, not significantly
different). (a) The target locus, into which the exogenous Tg is introduced by homologous recombination, is the mutated Hprt gene (ΔHprt) in the E14TG2a
cells. (b) The targeting vector contains the rat Cyp1a1 promoter, mouse prolactin (Prl) cDNA, and the 3′-UTR of bGH. (c) The resulting locus after homologous
recombination. The prolactin expression now is controlled by the Cyp1a1 promoter, which can be induced by I3C. Coding sequences of the prolactin gene are
shown as black columns. (B) The mRNA levels of prolactin in the liver of WT and the Tg mice with and without I3C at the age of 12 wk. Coding sequences of
the prolactin gene are shown as black columns. (C) The mRNA levels of prolactin in the pituitary gland are not changes by the Tg or by the administration of
I3C. (D) Plasma levels of prolactin of WT and the Tg mice with and without I3C.
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found that the ejection fraction of the left ventricle, an indicator of
cardiac function, was decreased from ∼85% to ∼50% in the Tg
mice fed IC3, but was not changed in the Tg mice fed NC (Fig. 4
A–E). The thicknesses of the intraventricular septum and the left
ventricular posterior wall were also significantly reduced in the
Tg mice fed I3C (Fig. 4 F and G). Thus, a threefold increase in
plasma prolactin concentration is sufficient to severely impair
cardiac function and structure.
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Fig. 2. Bidirectional change in arterial pressure by overexpression of prolactin is associated with changes in urinary excretion of nitrite/nitrate and in the
expression of 16K prolactin and its downstream genes (*P < 0.05 and **P < 0.01 vs. WT; NS, not significantly different). (A) sBP in WT and prolactin Tg male
mice on NC or on the I3C diet determined with a tail-cuff method. (B) Heart rate in WT and prolactin Tg mice fed NC or the I3C diet. (C) Urinary nitrite/nitrate
excretion. (D) Food consumption. (E) Renal expression of eNOS in WT and the prolactin Tg mice without and with I3C administration. (F) Immunoblot for
Ser1177-phosphorylated and total eNOS in the liver of WT and Tg mice without and with I3C administration. (G) Immunoblot for the full-length (23K)
prolactin and 16K prolactin in the plasma of WT and the Tg mice without and with I3C administration. (H) Renal expression of PAI-1 in WT and prolactin
Tg mice without and with I3C administration. (I) Renal expression of iNOS in WT and prolactin Tg mice without and with I3C administration.
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Fig. 3. Lack of eNOS abolishes the bidirectional change in arterial pressure by overexpression of prolactin (*P < 0.05 and **P < 0.01 vs. WT; NS, not sig-
nificantly different). (A) Plasma levels of prolactin of eNOS-deficient prolactin WT mice and the eNOS-deficient prolactin Tg mice with and without I3C. (B) sBP
in the eNOS-deficient prolactin WT mice and the eNOS-deficient prolactin Tg mice on NC or on the I3C diet. (C) Heart rate in the eNOS-deficient prolactin WT
mice and the eNOS-deficient prolactin Tg mice on NC or on the I3C diet.
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Discussion
In the present study, we have generated male Tg mice that have a
leaky prolactin Tg at the Hprt locus. The Tg is driven by a pro-
moter that is inducible by feeding chow containing IC3. When
the Tg mice are fed NC without IC3, their basal plasma prolactin
concentration is approximately twice that of WT mice fed NC,
their BP is approximately 10 mm Hg less than in WT mice,
and their urinary excretion of nitrate/nitrite is approximately
three times that of WT mice. When the Tg mice are fed chow
containing IC3, their plasma prolactin concentration increases to
approximately three times basal, their BP becomes approximately
25 mmHg higher than in WTmice, and their cardiac function and
structure are markedly compromised. In the absence of eNOS,
feeding IC3 has no effects. We show that the effects of increased
plasma concentrations of prolactin are mediated by its short form
(16 kDa).
In humans, several studies have shown that increased levels of
prolactin are associated with elevated arterial pressure (18, 19).
In the opposite direction, a loss-of-function SNP in the GPR10
gene, which codes for the prolactin-releasing peptide receptor, is
associated with reduced BP (20). Recently, a cohort study has
demonstrated that a higher daytime plasma prolactin level is
associated with an increased risk of incident hypertension among
postmenopausal women (21). These results imply that circulating
prolactin levels are positively correlated with BP in humans.
In animal experiments, whether changes in the expression of
prolactin cause different BP levels has been debatable. Acute i.v.
infusion of prolactin increases BP in rabbits (6). When ovine
prolactin was chronically given i.p. via an osmotic minipump in
rats, BP was decreased, which was associated with increased
extracellular fluid volume (7). It has also been reported that chronic
prolactin infusion caused an increase in urinary sodium, potassium,
and water excretion, but no significant changes in arterial pres-
sure in rats (8). A dopamine agonist lergotrile mesylate, which
suppresses prolactin secretion (7), and a rabbit antiserum to
rat prolactin significantly lowered BP in rats (22). In contrast,
prolactin has been shown to reduce BP in rabbits with pro-
gesterone-induced hypertension (23) and in spontaneously hy-
pertensive rats (24).
Prolactin increases NO production (25) by increasing in-
tracellular calcium in mouse mammary epithelial cells (26) and
by increasing the expression of carboxypeptidase-D, which re-
leases the NOS substrate L-arginine from the C terminus of
polypeptides (27, 28). Prolactin causes endothelium-dependent
vasodilation via prolactin receptors in the rat aorta (29).
It has recently been demonstrated that the 16-kDa form of
prolactin, which is cleaved out of prolactin by cathepsin-D and
matrix metalloproteinases, has antiangiogenic effects, whereas
the full-length prolactin has angiogenic effects (13, 30). Over-
expression of the 16 kDa impairs cardiac function (31). The
16-kDa prolactin has also been demonstrated to inhibit eNOS ac-
tivity by modulating intracellular calcium mobilization (15) and
activating protein phosphatase 2A, leading to dephosphorylation
and inactivation of endothelial NOS (16). The 16 kDa levels are
elevated in plasma, urine, and amniotic fluid obtained from women
with preeclampsia (4).
WT mice and healthy women have a decline in BP in preg-
nancy, but mice deficient in eNOS do not (32–34), suggesting
that eNOS is involved in the pregnancy-induced decrease in BP.
In the last third of pregnancy and during lactation, prolactin
levels in female mice normally become three to four times higher
than those in virgin females (32). Our Tg males fed NC have
plasma prolactin concentrations comparable to this, and, like the
pregnant mice, their BPs are less than in WT mice fed NC, and
their cardiac parameters are normal. The situation is completely
different when they are fed IC3; their plasma prolactin concen-
trations are threefold those of the Tg mice fed NC, their BPs are
in the hypertensive range, and their hearts are damaged.
The changes in BP we observed in our Tg mice were accom-
panied by the changes in urinary excretion of NO metabolites
nitrite/nitrate despite no changes in dietary intake of nitrite/nitrate,
suggesting that endogenous production of NO is changed by the
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Fig. 4. Cardiac dysfunction by marked overexpression of prolactin (*P < 0.05 and **P < 0.01 vs. WT; NS, not significantly different; TL, tibia length). (A–D)
M-mode echocardiography in WT and prolactin Tg mice with and without the I3C diet. (A) WT mice fed NC. (B) WT mice fed I3C diet. (C) Tg mice fed NC.
(D) Tg mice fed I3C diet. (E) Ejection fraction of the left ventricle. (F) Thickness of the intraventricular septum in diastole (IVSd). (G) Thickness of the left
ventricular posterior wall in diastole (LVPWd). (H) Left ventricular internal diameter in diastole (LVIDd).
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overproduction of prolactin. The total amount of eNOS was not
changed by the higher plasma concentrations of prolactin. However,
in agreement with published work showing that eNOS is activated
when its Ser1177 is phosphorylated by Akt-kinase and that prolactin
phosphorylates Akt-kinase (35–37), Ser1177-phosphorylated eNOS
was increased in the Tg mice fed NC. In contrast, Ser1177 phos-
phorylation was decreased in the Tg mice fed I3C, in agreement
with work showing that 16-kDa prolactin decreases phosphorylation
of Ser1177 (16). These findings, together with our finding that a lack
of eNOS almost totally abolished the alterations in BP by changes in
plasma prolactin levels, lead us to conclude that the full-length and
cleaved 16-kDa prolactin both change BP mainly via modulating
activity of eNOS. We also observed an increase in iNOS expression,
although lack of iNOS has no significant effects on plasma nitrite/
nitrate levels (38), and the changes we observed in iNOS expression
are minor compared with those that others have found to cause
decreases in BP (39, 40).
The levels of 16-kDa prolactin in the plasma of the Tg mice
fed I3C are more than those in WT, but are much less than those
of the full-length prolactin. This situation is similar to the pre-
vious finding that the levels of 16-kDa prolactin are increased in
the plasma, urine, and amniotic fluid of the patients with pre-
eclampsia compared with those of women with normal preg-
nancy, although, as in our mice, the amount of 16-kDa prolactin
is much less than that of the full-length prolactin (4). Why the
hypertensive effect of the 16-kDa form can overcome the de-
pressor effect of the full-length prolactin is poorly understood.
The two forms clearly differ in many ways. Thus, PAI-1 and
iNOS are downstream of 16-kDa prolactin but not of full-length
prolactin (12–14). The 16-kDa form, but not the full-length form,
requires the formation of a complex with PAI-1 to be active (41),
and their intracellular signaling pathways differ (42).
Postpartum cardiomyopathy occurs within the ninth month of
pregnancy to the fifth month postpartum, and is manifested by
hypertrophy or dilatation with a low ejection fraction (43). Our
findings that increased levels of full-length and 16-kDa prolactin
cause hypertension and cardiac dysfunction are in agreement
with the previously suggested link between the 16-kDa prolactin
and preeclampsia/postpartum cardiomyopathy.
In summary, we find that different degrees of elevated plasma
levels of prolactin have opposite effects: a decrease in BP caused
by increased production of NO when plasma prolactin is mod-
estly above normal, and an increase in BP together with cardiac
malfunction caused by decreased production of NO when plasma
prolactin is substantially increased. These findings, together with
the known association of greater-than-normal prolactin levels
with preeclampsia, suggest that pregnant women with high levels
of prolactin may need special attention.
Materials and Methods
Animals. We generated prolactin hypermorphic mice by inserting the single-
copy Tg comprising the rat Cyp1a1 promoter, mouse prolactin cDNA (do-
nated by Daniel I. H. Lintzer, Northwestern University, Evanston, IL), and the
3′-UTR of bGH into the Hprt locus in ES cells of the E14TG2a strain using
homologous recombination (Fig. 1A) (9). After positive selection with hy-
poxanthine (16 μg/mL), aminopterin (0.175 mg/mL), and thymidine (4.8 mg/mL),
the gene targeting was confirmed by Southern blot by using genomic DNA
digested by BamHI (9). After generation of the animals, genotyping of prolactin
hypermorphic mice was performed based on the presence or absence of the
junction between prolactin cDNA and the 3′-UTR of bGHwith conventional PCR
using the toe DNA as a template. The primers used for the genotyping are
as follows: forward, 5′-CAAGGTCATCAATGACTGCC-3′; reverse, 5′-ACAGTGG-
GAGTGGCATCTT-3′. The targeted mice were backcrossed into the C57BL/6
strain at least eight times before use.
IC3. Normal mouse chow supplemented with 0.3% IC3 was obtained
from Envigo.
Measurement of Biological Parameters. We measured systolic BP (sBP) and
pulse rate with the tail-cuff method (44). Plasma levels of prolactin were
studied with ELISA (Mouse Prolactin DuoSet; R&D Systems). Urine nitrite/
nitrate levels were studied with the Griess method (Nitrite/Nitrate Colori-
metric Assay; Cayman). Metabolic balance studies were performed by using
metabolic cages (Solo Mouse Metabolic Cage; Tecniplast). All animal pro-
tocols have been approved by the University of North Carolina Institutional
Animal Care and Use Committee.
Immunoprecipitation/Western Blot. The kidney was homogenated in immu-
noprecipitation buffer (50 mM Tris·HCl, pH 7.4, 150 mM NaCl, 50 mM
β-glycerophosphate, 30 mM NaF, 2 mM EDTA, 2 mM EGTA, 30 mM Na4P2O7,
2 mM Na3VO4, 1% Triton X-100) and protease inhibitors (1 mM PMSF, 5 μg/mL
leupeptin, 5 μg/mL antipain, 5 μg/mL pepstatin A, and 10 μg/mL aprotinin). The
homogenate was centrifuged at 1,000 × g to pellet the nucleus and debris.
Equal amounts of protein were incubated with an appropriate antiserum
and protein G agarose for 16 h at 4 °C. The proteins were fractionated by
SDS/PAGE (Criterion; Bio-Rad) and detected with Western blot by chem-
iluminescence (Supersignal West Pico; Thermo). The polyclonal antibody
against the N terminus of prolactin (Cell Signaling) and the monoclonal
antibody against GAPDH (Cell Signaling) were used for Western blot.
Quantitative RT-PCR. Total RNA was extracted from different tissues, and the
mRNAs were assayed by quantitative RT-PCR as previously described (45). The
primers and probes used to measure mRNAs are shown in Table S1.
Echocardiography. For analysis of heart function in mice, we used the Vevo
2100 v1.1.2 ultrasonograph system (VisualSonics) and a 30-MHz transducer.
Diastolic and systolic wall thickness, end-diastolic dimensions, and end-systolic
chamber dimensions of the left ventricle weremeasured by using a parasternal
short-axis view. Allmeasurementsweredone in theUniversity of NorthCarolina
Rodent Advanced Surgical Models Core according to the American Society of
Echocardiography guidelines.
Statistical Analysis. Data are expressed as means ± SEs. To compare groups,
we used one-factor ANOVA. Post hoc pairwise comparisons were performed
by Tukey–Kramer honestly significance differences test with JMP software
(version 5.1.2; SAS). When the number of animals was fewer than five, a
nonparametric Kruskal–Wallis test was used to compare the groups.
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